
 
 
 
 
 
 
 
 
   
   1 . A yeast strain of  Phaffia rhodozyma , wherein the yeast strain is characterized in that it is capable of producing a greater amount of carotenoid when cultivated in a yeast growth medium comprising at least 3% (w/v) carbon source compared to when cultivated in a yeast growth medium comprising 1% (w/v) carbon source; wherein the yeast strain comprises a genome comprising:
 i) a point mutation at position 2028187 in scaffold 69, at the upstream region of gene XDEN_04715, and/or   ii) a point mutation at position 1540450 in scaffold 79 at gene XDEN_05955.   
 
     
   2 . The yeast strain of  claim 1 , wherein the yeast strain further comprises a genome comprising at least one, at least two, at least three, or at least four of iii) to vi) defined in the following:
 iii) two-point mutations at positions 318703 and 318738 in scaffold 242, upstream to gene XDEN_00738;   iv) two-point mutations at positions 855 and 1020 in scaffold 88, downstream to gene XDEN_06229;   v) a deletion of two bases immediately following position 213879 in scaffold 162, located at the gene XDEN_00195; and   vi) two-point mutations at positions 84078 and 84206 in scaffold 24, at the gene XDEN_01573.   
 
     
   3 . The yeast strain of  claim 1 , wherein the point mutation at position 1540450 in scaffold 79 at gene XDEN_05955 is a G to A change, resulting in an amino acid exchange of proline to serine. 
 
     
   4 . The yeast strain of  claim 1 , wherein the point mutation(s) is (are) present in at least one, at least two, or in all alleles of said gene(s). 
 
     
   5 . The yeast strain of  claim 1 , comprising a genome comprising at least one, at least two, at least three, at least four, at least five, or at least six of the nucleotide sequences of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6. 
 
     
   6 . The yeast strain of  claim 1 , wherein the yeast strain is characterized in that it is obtainable from a  Phaffia rhodozyma  strain selected from the following:
 AF-02 (deposit NCYC 4294),   AF-03 (deposit NCYC 4337),   AF-04 (deposit NCYC 4336),   AF-05 (deposit NCYC 4345),   AF-06 (deposit NCYC 4344),   AF-07 (deposit CBS 146150),   AF-08 (deposit NCYC 4389),   AF-09 (deposit NCYC 4388),   AF-10 (deposit NCYC 4406), and   AF-11 (deposit NCYC 4405).   
 
     
   7 . The yeast strain of  claim 1 , wherein the yeast strain is selected from the following:
 AF-02 (deposit NCYC 4294),   AF-03 (deposit NCYC 4337),   AF-04 (deposit NCYC 4336),   AF-05 (deposit NCYC 4345),   AF-06 (deposit NCYC 4344),   AF-07 (deposit CBS 146150),   AF-08 (deposit NCYC 4389),   AF-09 (deposit NCYC 4388),   AF-10 (deposit NCYC 4406), and   AF-11 (deposit NCYC 4405).   
 
     
   8 . The yeast strain of  claim 1 , wherein the yeast strain is characterized in that it is capable of producing a greater amount of carotenoid when cultivated in a yeast growth medium comprising 5% (w/v) carbon source compared to when cultivated in a yeast growth medium comprising 1% (w/v) carbon source. 
 
     
   9 . A Process for producing carotenoid by fermentation of a yeast strain according to  claim 1 . 
 
     
   10 . A method of obtaining a carotenoid over-producing yeast strain of  Phaffia rhodozyma  comprising:
 a) inducing mutation of a yeast strain of  Phaffia rhodozyma  by incubating it under mutagenic conditions, and   b) selecting a carotenoid over-producing yeast strain obtained thereof,   
 wherein the carotenoid over-producing yeast strain selected in step b) is characterized in that it is capable of producing a greater amount of carotenoid when cultivated in a yeast growth medium comprising at least 3% (w/v) carbon source compared to when cultivated in a yeast growth medium comprising 1% (w/v) carbon source; wherein the yeast strain which is selected comprises a genome comprising:
 i) a point mutation at position 2028187 in scaffold 69, at the upstream region of gene XDEN 04715, and/or 
 ii) a point mutation at position 1540450 in scaffold 79 at gene XDEN_05955. 
 
 
     
   11 . The yeast strain of  claim 1 , wherein the carbon source is selected from the group consisting of glucose, fructose, sucrose, maltose, raffinose, xylose, or a combination thereof. 
 
     
   12 . A carotenoid over-producing yeast strain obtained by the method of  claim 10 . 
 
     
   13 . The yeast strain of  claim 1 , wherein the carotenoid is at least 50% (w/w) astaxanthin. 
 
     
   14 . Use of the yeast strain of  claim 1  to produce a product comprising astaxanthin, wherein the product is a dietary supplement, a nutritional supplement, a food supplement, a beverage supplement, a food additive or a feed additive such as a feed colorant; a pharmaceutical composition for human health, for example for the treatment of Parkinson's disease, cardiovascular diseases, in promoting rehabilitation after heart attack, or for improving the function of the immune system; or a cosmetic composition. 
 
     
   15 . The process of  claim 9 , wherein the carbon source is selected from the group consisting of glucose, fructose, sucrose, maltose, raffinose, xylose, or a combination thereof. 
 
     
   16 . The method of  claim 10 , wherein the carbon source is selected from the group consisting of glucose, fructose, sucrose, maltose, raffinose, xylose, or a combination thereof. 
 
     
   17 . The process of  claim 9 , wherein the carotenoid is at least 50% (w/w) astaxanthin. 
 
     
   18 . The method of  claim 10 , wherein the carotenoid is at least 50% (w/w) astaxanthin. 
 
     
   19 . The carotenoid over-producing yeast strain of  claim 12 , wherein the carotenoid is at least 50% (w/w) astaxanthin. 
 
     
   20 . Use of the carotenoid over-producing yeast strain of  claim 12  to produce a product comprising astaxanthin, wherein the product is a dietary supplement, a nutritional supplement, a food supplement, a beverage supplement, a food additive or a feed additive such as a feed colorant; a pharmaceutical composition for human health, for example for the treatment of Parkinson's disease, cardiovascular diseases, in promoting rehabilitation after heart attack, or for improving the function of the immune system; or a cosmetic composition. 
 
   
 
 
 
 
 
 
 
 
